MARKET

GPCR

GPCR

Structure Therapeutics Inc ADR
NASDAQ
17.12
-0.24
-1.38%
After Hours: 16.95 -0.17 -0.99% 19:58 11/19 EST
OPEN
17.53
PREV CLOSE
17.36
HIGH
17.95
LOW
16.88
VOLUME
691.65K
TURNOVER
--
52 WEEK HIGH
94.90
52 WEEK LOW
16.88
MARKET CAP
1.23B
P/E (TTM)
-4.3058
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GPCR last week (1109-1113)?
Weekly Report · 3d ago
Structure Therapeutics price target lowered to $117 from $126 at Morgan Stanley
TipRanks · 6d ago
Structure Therapeutics: Buy Rating and $70 Price Target Unchanged on Obesity Drug Potential
TipRanks · 11/12 12:26
Structure Therapeutics: Oral GLP-1 Catalysts and Strong Cash Position Support an Attractive Entry Ahead of SWITCH Results
TipRanks · 11/12 07:05
Structure Therapeutics price target lowered to $107 from $111 at Canaccord
TipRanks · 11/10 16:56
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Hinge Health, Inc. Class A (HNGE) and HealthStream (HSTM)
TipRanks · 11/10 13:30
Piper Sandler Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 11/10 12:55
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Canaccord Genuity
TipRanks · 11/10 12:46
More
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Webull offers Structure Therapeutics Inc (ADR) stock information, including NASDAQ: GPCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GPCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GPCR stock methods without spending real money on the virtual paper trading platform.